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Summary: Nitric oxide synthase (NOS) is regulated by protein-protein interactions.  We had earlier shown that PKG 
inhibits activated NOS in endothelial cells and speculated that PKG phosphorylation of NOS terminates its activity. The 
present work examines if PKG activation increases breakdown of NOS. Diamino-fluorescein fluorescence spectrometry of 
real time NO production was used to establish that isolated ovine lung microvascular endothelial cells responded to PKG 
modulation as previously reported. Fluorescence activated cell sorter (FACS) analysis was used to establish that 8-Br-
cGMP, a PKG activator, caused carboxy terminal deletion on NOS, a sign of degradation. Western blot analysis was used 
to investigate NOS fragments in control and 5 min 8-Br-cGMP treated cells. PKG activator 8-Br-cGMP, at 20 nM, 200 
nM, and 2 μM,  decreased nitric oxide production in a dose dependent manner (p<0.05 in all cases).  PKG inhibitors: 100 
μM Rp-8-Br-PET-cGMPS, 50 nM Rp-8-pCPT-cGMPS, or 4 μM Rp-8-Br-cGMPS Na significantly increased NO 
production (p<0.05) showing that PKG normally inhibits basal NO production.  8-Br-cGMP (100 nM) abrogated the 
elevation in NO production produced by the PKG inhibitors.  FACS analysis revealed that PKG decreased NOS carboxy 
terminal labeling.  Western blot analysis revealed that 8-Br-cGMP increased N-terminal serine-116 phosphorylated NOS 
fragments of molecular weights of about 60, 50 and 35 kDa. PKG may be a post-activation inhibitor of NOS, possibly 
important for the degradation of the spent enzyme. 
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Nitric oxide synthase (NOS) is regulated by protein-
protein interactions.  Recently, we used real time 
measurement of basal NOS function by DAF assay in 
live endothelial cells and showed that PKG inhibits 
NOS.  We speculated that PKG phosphorylation of 
NOS terminates its activity (John et al., 2008; John, 
2010; John and Raj, 2010).  Using FACS analysis, we 
also showed that PKG caused molecular and 
phosphorylation changes on the NOS molecule under 
basal conditions (John and Raj, 2010). In unpublished 
work, we have observed a differential subcellular 
colocalization of NOS with caveolin-1 versus PKG 
under basal conditions. NOS co-localizes with 
caveolin-1 at plasmallemal and golgi sites and with 
PKG in the cytosol, ER network, and nuclear sites, 
especially in vesicular formation, under basal 
conditions.  This may be an indication that the two 
inhibitors have different effects on NOS function. 
Caveolin-1 appears to be a pre-activation inhibitor of 
nascent NOS while PKG appears to be a post-
activation inhibitor of spent NOS.  Our present 
hypothesis is that PKG deactivates active NOS and 
subjects the spent enzyme to degradation.  In this 
study, western blot analysis was used to observe 
remnant NOS N-terminal fractions obtained from live 
endothelial cells in control and cGMP treated cells. 
The present report is a snippet of evidence that 
PKG phosphorylation of NOS precedes NOS 
degradation.  More understanding of the endogenous 
regulation of basal NOS activity and the metabolic 
cycle of the NOS enzyme can help us develop even 
more precise therapeutic strategies for regulating 
NOS in disease conditions. 
 
MATERIALS AND METHODS 
Animals 
This work was reviewed and approved by the Animal 
Care and Use Review Committee of Los Angeles 
Biomedical Research Institute.  Newborn lambs aged 
<2 d were obtained from Nebeker Ranch (Lancaster, 
CA).  Lung microvascular endothelial cell cultures 
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were isolated from the lambs and characterized as 
recently published (John et al., 2008; John, 2010).   
Demonstration of role of PKG in regulation of 
NOS activity 
To demonstrate the immediate effect of PKG 
activation on basal NOS activity of the cells, a cell 
permeable cGMP analogue, 8-Br-cGMP (Fluka 
Biochemika, Buchs, Switzerland), in concentrations 
of 20 nM, 200 nM, or 2 μM, was added to confluent 
microcultures with DAF fluorophores in a reaction 
medium comprised of PBS plus 5% phenol-red free 
DMEM, and 1% Gibco® antibiotic/antimycotic 
mixture.  To demonstrate the effect of inhibition of 
PKG on basal NOS activity, cells were incubated 
with guanosine-3’-5’-cyclic monophosphoro 
thionate-8-Br-Rp isomer Na salt (Calbiochem EMD, 
San Diego, CA) in concentrations of 25 nM, 75 nM 
and 125 nM 30 min before the DAF combination was 
added.  Experiments were completed as previously 
reported (John, 2010; John and Raj, 2010). 
Demonstration of the effects of PKG inhibitors on 
PKG  
Cells were preincubated with PKG inhibitors, 100 
μM Rp-8-Br-PET-cGMPS (Biolog, Hayward, CA), or 
50 nM Rp-8-pCPT-cGMPS (Biomol, Plymouth 
Meeting, PA), or 4 μM  Rp-8-Br-cGMPS Na 
(Calbiochem EMD, San Diego, CA), 30 min before 
the DAF combination was added and with or without 
PKG activator, 100 μM 8-Br-cGMP, which was 
added 5 min before DAF was added.  NO produced 
was measured after 5 min.  
Fluorescence of NO produced by cells was 
calculated as the difference above fluorescence 
detected in the presence of NOS inhibitor, 200 μM L-
NAME.  Studies were done thrice.  Representative 
data from single experiments (N=6) are presented. 
Fluorescence activated cell sorter demonstration 
of the effect of 8-Br-cGMP on NOS C-terminal 
expression.   
LMVECs were trypsinized and washed with PBS.  
Cell suspensions in PBS were split equally into 
control and 5 μM 8-Br-cGMP (5 minutes) treatment 
groups and immunolabled for detection of the C-
terminal of the NOS molecule by FACS as earlier 
described (John and Raj, 2010) using a monoclonal 
antibody (1: 100) for specific probing.  The mouse 
anti NOS antibody used was developed against the 
immunogen bovine eNOS c-terminal amino acids 
1185-1205 (Sigma, St Louis MO).  The FACS 
analysis system comprised of a BD FACS Calibur 
and a MacIntosh Q3 FACS workstation.  The 
fluorescence intensities of sample populations were 
determined by Cell Quest software. 
Detemination of the effect of 8-Br-cGMP on the 
immunoblot expression of N-terminal serine 116 
phosphorylated NOS in endothelial cells.   
To test the effect of 8-Br-cGMP on NOS N-terminal 
expression, serine 116-NOS immunolabeling in 
endothelial cells with western blot analysis was used.   
LMVECs from a single suspension were equally 
seeded in 100mm diameter dishes. Five-day-
confluent triplicate monolayers were used for 
controls and identical triplicate monolayers of sibling 
cells were used as tests treated with 300 nM 8-Br-
cGMP (Calbiochem, CA) for 15 min before routine 
immunoblot analysis.  After electrophoresis and 
transfer of proteins to a membrane, the membrane 
was blocked with 5% non-fat milk and then incubated 
with a primary antibody against phosphorylated 
serine-116 region of NOS (1: 200 concentration, 
Sigma, St. Louis) at 4C for 24h with gentle rocking.  
The experiment was completed as reported (John et 
al., 2008).  Protein bands were visualized by 
horseradish peroxidase conjugated secondary 
antibodies (Amersham, Buckinghamshire, UK) using 
Super Signal® West Pico Chemiluminescent 
Substrate kit (Pierce, Rockford, IL) to prepare the 
developing solution.  Membranes were exposed to 
Blue Lite Autorad Films (ISC BioExpress, Kaysville, 




Protein Kinase G inhibits basal NOS activity in 
neonatal ovine lung microvascular endothelial 
cells.   
 All data were corrected for extraneous fluorescence 
due to DAF autofluorescence as previously reported 
(John et al., 2008; John 2010).  L-NAME decreased 
fluorescence produced by NO in the LMVEC 
microcultures from the basal value of 3783.14 ± 
51.01 to 1933.33 ± 16.15 (N=6, p<0.02).  The 
analogue of cGMP, 8-Br-cGMP, which activates 
PKG decreased basal NO production when given in 
concentrations of 20 nM, 200 nM and 2 μM 8-Br-
cGMP.  The fluorescence was decreased from the 
basal value of 3783.14 ± 51.01 to 2780.00 ± 21.79, 
2439.25 ± 16.09, and 1831.25 ± 15.45 respectively in 
5 min. The significance values were p<0.05, p<0.004, 
and p<0.004 respectively.  The results were converted 
to percentage change in basal NO and plotted against 
drug concentrations (Figure 1, second to fourth bars, 
N=6).  
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PKG activation and inhibition have opposite effects on basal NO production in microvascular endothelial cells.   Using 
paired t-tests, the inhibitory responses to PKG activation were all significant at p<0.05 (values shown).  The enhancement 
of NO production by the PKG antagonist was significant at 125 nM (p<0.01).  Studies were done at least thrice with 
similar results.  Figure shows means ± SE of representative data with significance levels of differences from basal values 




Enhanced nitric oxide production by PKG inhibitors is reversed by 8-Br-cGMP. Figure is data, mean ± SE, from a 
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FACS analysis shows that PKG activation decreases NOS 
carboxy terminal antibody labeling. In the analysis of 
fluorescein tagged cells, 10,000 events were taken per 
sample.  Upper channels show control cells and lower 
channels show PKG activator 5 µM 8-Br-cGMP treated 
cells. The fluorescence intensity range (y-axis) was 
decreased by PKG activation.  The mean fluorescence 
value for cells gated at 101 fluorescence units (FU) was 
98.48 ± 2.13 for controls and 38.62 ± 1.18 for 8-Br-cGMP 
treated cells, a 60.8 % decrease by PKG activation.    
Figure is a representative of two studies. 
 
Protein Kinase G inhibitors enhance NO 
production in untreated neonatal ovine lung 
microvascular endothelial cells.   
PKG inhibitor, guanosine-3’-5’-cyclic 
monophosphoro thionate-8-Br-Rp isomer Na salt in 
concentrations of 25 nM, 75 nM and 125 nM 
increased basal NO production from 3539.00 ± 28.41 
to 3554 ± 30.46, 3881.83 ± 36.47, and 4598.33 ± 
50.24 respectively (N= 6 per group).  The PKG 
inhibitor at a concentration of 125 nM significantly 
increased basal NO (p<0.01).  The results were 
converted to percentage change in basal NO 
production and plotted against drug concentrations 
(Figure 1, last 3 bars).   
In another study, the effect of PKG inhibitors 
without and with cGMP were compared using 
fluorescence of NO produced by cells calculated as 
the difference above fluorescence detected in the 
presence of NOS inhibitor 200 uM L-NAME.  The 
PKG activator 100 μM 8-Br-cGMP decreased NO 
production from the basal value of 1856.7 ± 62.6 to 











































PKG activation increases anti-serine116-NOS antibody 
labeling of NOS N-terminal fractions in normal endothelial 
cells.  The film developed from western blotting showed 
that serine-116 phosphorylated NOS can be normally 
found in control cells as enzyme fragments and that these 
fragments are increased by PKG activation. 
In this study, comparing the effects of 
preincubation with three PKG inhibitors in sibling 
cells, 100 μM Rp-8-Br-PET-cGMPS, 50 nM Rp-8-
pCPT-cGMPS, or 4 μM Rp-8-Br-cGMPS enhanced  
 Nig. J. Physiol. Sci. 26 (2011): John T.A 
PKG pro-degradation inhibition of NOS   5 
 
basal NO production from 1856.7 ± 62.6 to 2362.7 ± 
55.5 (p<0.04), 2316.7 ± 55.13, and 2358 ± 47.4 
respectively (N=6, p<0.05 in all cases) (Figure 2, 
third to fifth bars).  The effect of the PKG inhibitors 
was attenuated by 100 μM 8-Br-cGMP given with 
DAF to give values of 2001.5 ± 10.7, 1864 ± 123.2, 
1981 ± 16.9 (p=0.03, p=0.056, p=0.008 respectively, 
N=6 in all cases) (Figure 2, last three bars). 
PKG activation decreases NOS carboxy terminal 
whole-cell immunofluorescence expression.   
The treatment of cells with 5 μM 8-Br-cGMP caused 
decrease in NOS detection by the NOS carboxy 
terminal moiety primary antibody given less than 5 
min before fixation.  In the FACS analysis of 
fluorescein tagged cells, 10,000 events were taken per 
sample.  The mean fluorescence value for cells gated 
at 101 fluorescence units (FU) was 98.48 ± 2.13 for 
controls and 38.62 ± 1.18 for 8-Br-cGMP treated 
cells, a 60.8 % decrease by PKG activation (Figure 
3).  A small proportion of 0.8% of the controls and 
0.19% of the 8-Br-cGMP treated had greater than 101 
FU, a 75.25 % decrease by 8-Br-cGMP.   
PKG activation increases N-terminal serine116 
phosphorylated NOS immunoblot expression. 
Control endothelial whole cell lysates showed the 
presence of serine 116 phosphorylated NOS 
fragments.  These were picked up in bands 
representing molecular weights of 60, 50 and 35 kDa 
(Figure 4).  Lysates of sibling cells treated with 8-Br-
cGMP and expressing similar actin contents showed 
an increased expression of serine 116 phosphorylated 
NOS bands.  The mean percentage increase in band 
density for each NOS protein N-terminal fraction is 
plotted and ranged from 29% - 278%, a significant 
increase in all cases (Figure 4). 
DISCUSSION 
The importance of nitric oxide synthase (NOS) which 
produces nitric oxide (NO) for vasodilatation and 
other vascular functions (Furchgott and Vanhoutte, 
1989; Palmer et al., 1987; Ignarro et al. 1987) has 
made this enzyme a topic for in-depth research in the 
past 20 years.  Inadequate NO leads to endothelial 
dysfunction. Diseases such as sexual dysfunction, 
pulmonary hypertension, heart failure, and 
atherosclerosis are linked to endothelial dysfunction 
involving nitric oxide synthase (Arnal et al., 1999; 
Fostermann and Munzel 2006).     We have been 
studying how basal NO production is controlled in 
endothelial cells (John et al., 2008; John, 2010; John 
and Raj, 2010).  Similar to our earlier publications, 
we show here, using DAF assays, that cGMP, a PKG 
activator, decreases NOS function in producing nitric 
oxide in live endothelial cells (John, 2010; John and 
Raj, 2010) (Figure 1 and 2).  The present and the 
published data indicate that PKG is involved in the 
termination of basal NOS activity. The PKG 
activator, 8-Br-cGMP, inhibits basal NO production 
in a dose-dependent manner (Figure 1).  Three 
different PKG inhibitors enhanced basal NO 
production in cells that received no other drug 
(Figure 2) and the effect is reversed by 8-Br-cGMP.   
It appears that the immediate effect of PKG inhibition 
is that basally active NOS is potentiated and 
enhanced NO is detected.  Similar to earlier 
publication also (John and Raj, 2010), we show here 
that in-cell immunolabeling of carboxy-terminal of 
NOS is decreased by cGMP in FACS analysis 
(Figure 3), therefore PKG may be causing deletion of 
carboxy terminal of NOS (possibly a degradative 
deactivation of the active enzyme).   
Figure 4 is a western blot of serine 116 
phosphorylated NOS appearing in molecular weight 
fragments of about 60, 50 and 35 kDa, an indication 
that the N-terminal remnants of NOS may be 
normally found in control cells and may be increased 
by PKG activation.  From previous publication, 
apparently, 8-bromo-cGMP instantaneously causes 
both increase in phosphorylated serine 116 N-
terminal recognition and decrease in phosphorylated 
serine 1177 carboxy terminal recognition of NOS 
protein in these quiescent endothelial cells (John and 
Raj, 2010).   
In contrast to decreased carboxy terminal labelling 
observed, endothelial cells with added cGMP appear 
to display more N-terminal immunolabelling of NOS 
than controls (Figure 4).  Decreased C-terminal and 
increased N-terminal detection may be indicating that 
degradation of NOS begins at the carboxy terminus 
and the N-terminus may not be subjected to the same 
process of degradation as the carboxy terminus or its 
degradation lags behind that of the carboxy terminus. 
If this were the case, NOS-N-terminal detection by 
western blotting should be the same for controls and 
for cGMP treated cells.  The NOS N-terminal 
accumulation observed by western blotting (Figure 4) 
may indicate that this fragment is actually retained in 
the cell and normally utilized.  Antibodies against 
serine 116-phosphorylated NOS, (serine 116 being in 
the N-terminal region) showed punctuate and 
vesicular immunoflourescence in the ER network and 
in the nuclear regions of these endothelial cells (John 
et al., 2008).   If the N-terminal fragment is relocated 
and transferred to the nuclear region it is hypothetical 
that it may actually act as a transcription factor for the 
production of new NOS enzyme in normal 
endothelial cells.   
In the present study, the duration of exposure of 
the endothelial cells to cGMP is only 5 minutes and is 
probably not enough time to observe a genomic 
effect.  Rather, it appears that the rate of production 
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of the N-terminal fragment (by NOS degradation) in 
the endothelial cells  with added cGMP (Figure 4) is 
faster than the basal rate of a hypothetical utilization 
of the N-fragment (such as translocation of the N-
terminal to the nucleus and its utilization to generate 
fresh enzyme), therefore it accumulates.  This may be 
a snippet of evidence that NOS is replenished by a 
PKG-dependent feedback process to maintain basal 
NO production in normal endothelial cells.  We need 
to study this in depth. It is not known how NOS is 
continually replenished to sustain basal NO 
production under physiologic conditions, a vital 
function in the cardiovascular system. 
 To follow up the speculation of this report, we 
would need kinetics comparison of the effects of 
cGMP on the rate and duration of inhibition of NOS 
enzyme and NO production, the rate of generation of 
N-terminal fragments and their stability, and the rate 
of de novo production of NOS enzyme in normal 
cells and in cells with disturbed vesicular processes. 
We would also need to study NOS N-terminal 
permeated cells to determine if this molecular 
fragment is truly involved in NOS transcription and 
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